comparing midostaurin to next-generation flt3 inhibitors in the frontline treatment of flt3-itd aml
Published 11 months ago • 345 plays • Length 2:08Download video MP4
Download video MP3
Similar videos
-
1:40
second-generation flt3 inhibitors in the treatment of flt3-itd aml
-
1:12
the value of flt3 inhibitors in aml and focus for future trial designs
-
4:47
the use of flt3 inhibitors in aml
-
2:40
an overview of the safety profile of flt3 inhibitors in aml
-
2:55
the importance of flt3 inhibitors in aml and factors to consider when choosing between these agents
-
3:31
update on quantum-first: quizartinib soc chemotherapy & as continuation therapy in flt3-itd aml
-
4:34
the genetics of acute myeloid leukemia (aml)
-
6:43
flt3 mutations’ impact on prognosis and treatment in aml
-
1:59
optimizing the use of flt3 inhibitors in aml: sequencing, post-transplant maintenance & more
-
1:03
targeted therapies in newly diagnosed aml: bcl2, flt3 and idh inhibitors
-
0:59
midostaurin: a step forward in the treatment of flt3-mutated aml
-
2:29
combining menin/flt3/bcl2 inhibition as a treatment approach in flt3/npm1 double mutated aml
-
3:42
midostaurin in c-kit or flt3-itd mutated t(8;21) aml
-
3:21
the prognostic impact of flt3-itd and flt3-tkd in npm1-mutated aml
-
2:20
best treatment strategy for flt3 itd aml
-
1:27
incorporating new technologies into the real-life classification of aml to guide treatment decisions
-
3:56
radius results: midostaurin reduces relapse after asct in flt3-itd aml
-
1:30
combinations with flt3 inhibitors: the way forward for aml treatment
-
1:32
integrating midostaurin into flt3 positive aml treatment
-
1:57
insights into the treatment of patients with flt3-mutated aml & the role of maintenance therapy
-
1:21
gemtuzumab-based induction chemotherapy with midostaurin in flt3-mutated aml
-
2:35
quizartinib for frontline flt3-itd aml: updated results from the quantum-first trial